Investor

Precision Genomics (OTC:LUDG) is always looking to work with investors wanting to help fund our campaign of transforming healthcare forever—and profit in the process.

Company Overview

Changing the future of medicine forever. Thanks to proprietary mRNA technology, powered by sophisticated deep machine learning, Precision Genomics’ solutions deliver truly unique insight to the entire medical field. As Precision Genomics continues to become a dominant force in the industry, we work harder than ever to stay true to our core mission and values. The name Precision Genomics will remain synonymous with innovation, transparency and accessibility—to our teams, clients, shareholders, and the world. Always.

Have Your Share in Change.

Interested in becoming a shareholder? Precision Genomics is always looking to work with investors wanting to help fund our campaign of transforming healthcare forever—and profit in the process.

Recent PR

Ludwig Enterprises Releases Annual 2022 Shareholder Letter

Management Reports Significant Growth and Development

SPARKS, NV / ACCESSWIRE / December 21, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, Inc., a leading-edge innovator of inflammatory genetic biomarkers to diagnose and manage chronic diseases, is pleased to announce the annual shareholder letter for 2022.

Highlights from the shareholder letter include:

Ludwig has made exciting changes in the past 4-6 months, including the acquisition of mRNA genomic technology with the potential to revolutionize healthcare.
Ludwig has filed a patent for their PG MRNA Inflammatory Index™ and launched a subsidiary, MyRNA for Life, Inc., to market an antioxidant nutraceutical formulation that could modulate inflammatory substances released by immune system cells.
Key milestones and value drivers for 2022 include signing up for the SRAX Shareholder Platform, acquiring assets and launching subsidiaries, filing patents and trademarks, attending conferences such as LD Micro Conference in Los Angeles, CA, meeting with investment banks, and preparation of an IPO filing with law firm MSK, Los Angeles CA & New York NY.

The complete shareholder letter can be found here:

Complete Shareholder Letter LUDG (Click Link for PDF)

Ludwig Enterprises Acquires Cutting-Edge Dietary Supplement Formula

MyRNA for Life™ Ready for Launch Q1, 2023

SPARKS, NV / ACCESSWIRE / December 6, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, Inc., a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce the acquisition of a nutraceutical formula from Xikoz, Inc. with a planned product release through MyRNA for Life, Inc. in Q1 of 2023.

Ludwig Enterprises Announces Progress Towards Planned IPO (S1 Filing)

NASDAQ Up-listing is Planned Upon Approval

SPARKS, NV / ACCESSWIRE / November 17, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, Inc., a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce that the company is planning to file a form S-1 registration statement. The company has engaged the Newlin Law Firm to complete the S1 registration statement. Additional needed steps include completing a PCAOB (SEC Peer Reviewed) audit and retaining a professional firm to research and complete our business plan.

Precision Genomics (a Ludwig Company) Revealed Major Medical News at a Sequire Spotlight Interview

Dr. Hausman Addressed How Precision Genomics mRNA technology can be a real breakthrough for significant chronic diseases.

SPARKS, NV / ACCESSWIRE / November 16, 2022 / (OTC PINK:LUDG) Ludwig Enterprises and Precision Genomics, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, Blog Title: Precision Genomics Announces SEQUIRE Spotlight Featuring Dr. Marvin S. Hausman MD.

Precision Genomics’ New mRNA Technology May Be a Solution to Help Diagnose and Establish Treatment for Long Covid

Long Covid (the long-term effects of Covid), or chronic Covid, can include a wide range of ongoing health problems; these conditions can last weeks, months, or longer.

Ludwig’s Genomic-Based mRNA Inflammatory Index - A Ground-Breaking Technology

SPARKS, NV / ACCESSWIRE / September 28, 2022 / (OTC PINK:LUDG)Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce more detail on this crucial technology, cooperative contracts, and current applications.

This technology’s potential medical and commercial value is revealed in a Research and Markets via Business Wire titled: “Global Biochips Market Report 2022: Increasing Adoption of Personalized Medicine Drives Growth.” “The rising prevalence of chronic diseases, such as cancer and diabetes, has increased demand for early diagnosis. In addition, the increasing adoption of personalized medicine and point-of-care (POC) testing is estimated to propel market growth.” “Global biochip market expected to reach USD 34.35 billion in 2030.”

Ludwig Files a Patent That Could Be a Major Technology Breakthrough in Healthcare

SPARKS, NV / ACCESSWIRE / September 22, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce that the Company has filed a patent on proprietary technology, the “Ludwig mRNA Inflammatory Index™.” The patent covers the application of messenger ribonucleic acid (mRNA) in diagnosing, managing, and evaluating inflammatory disease patient treatment response in heart disease, diabetes, autoimmune disease, preeclampsia, and bladder, colon, and breast cancer.

Ludwig Enterprises and Emerson Urology Associates Plan Bladder Cancer BCG Immunotherapy Study

SPARKS, NV / ACCESSWIRE / September 20, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce that the Company has started discussions with Emerson Urology Associates, Concord, MA regarding initiation of a clinical study to evaluate the response of bladder cancer patients to BCG immunotherapy. A confidentiality agreement has been signed with Dr. John Libertino, MD, Director of Emerson Urology Associates.

With a New CEO, Prestigious Medical Team, and New Business Direction, LUDG Paves the Way for a Potential Future IPO

SPARKS, NV / ACCESSWIRE / August 18, 2022 / Ludwig Enterprises, Inc. (OTC PINK:LUDG), a provider of innovative medical technologies, announced today another significant milestone in the company’s recently announced new business model. The company has also engaged a public accounting firm as its independent auditor while retaining the services of Newlan Law Firm, PLLC, an experienced Flower Mound, Texas, securities firm, to assist the company in achieving its future IPO aspirations. The company remains committed to increasing operational transparency and to becoming an SEC-reporting company in the near term.

Ludwig Appoints Dr. Kyle Ambert Ph.D. to Scientific Advisory Board

SPARKS, NV / ACCESSWIRE / July 21, 2022 / Ludwig (OTC PINK:LUDG) is pleased to announce that Dr. Marvin S. Hausman MD, Chairman of Ludwig’s Scientific Advisory Board (SAB) has appointed Dr. Kyle H. Ambert, PhD to its SAB, effective immediately. Dr.Ambert has also agreed to become a consultant to Ludwig and its subsidiary mRNA for Life, Inc. and will assist the Company in designing clinical studies and analyzing their results.

Precision Genomics, A Ludwig Enterprises Company